vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Merchants Bancorp (MBIN). Click either name above to swap in a different company.
Merchants Bancorp is the larger business by last-quarter revenue ($175.2M vs $168.4M, roughly 1.0× Esperion Therapeutics, Inc.). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 4.8%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Ameris Bancorp is an American bank holding company headquartered in Atlanta, Georgia. Through its bank subsidiary, Ameris Bank, the company operates full-service branches in Georgia, Alabama, Florida, North Carolina and South Carolina, and mortgage-only locations in Georgia, Alabama, Florida, North Carolina, South Carolina, Virginia, Maryland, and Tennessee. The company offers online and mobile banking options for both consumers and businesses.
ESPR vs MBIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $175.2M |
| Net Profit | — | $67.7M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 38.6% |
| Revenue YoY | 143.7% | — |
| Net Profit YoY | — | 16.3% |
| EPS (diluted) | $0.32 | $1.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $175.2M | ||
| Q4 25 | $168.4M | $185.3M | ||
| Q3 25 | $87.3M | $171.1M | ||
| Q2 25 | $82.4M | $179.2M | ||
| Q1 25 | $65.0M | $145.9M | ||
| Q4 24 | $69.1M | $193.8M | ||
| Q3 24 | $51.6M | $149.6M | ||
| Q2 24 | $73.8M | $159.5M |
| Q1 26 | — | $67.7M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $54.7M | ||
| Q2 25 | $-12.7M | $38.0M | ||
| Q1 25 | $-40.5M | $58.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $61.3M | ||
| Q2 24 | $-61.9M | $76.4M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 39.9% | ||
| Q3 25 | -11.4% | 37.8% | ||
| Q2 25 | 8.6% | 27.3% | ||
| Q1 25 | -34.0% | 52.4% | ||
| Q4 24 | -6.4% | 66.0% | ||
| Q3 24 | -31.0% | 54.4% | ||
| Q2 24 | 3.5% | 62.2% |
| Q1 26 | — | 38.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 32.0% | ||
| Q2 25 | -15.4% | 21.2% | ||
| Q1 25 | -62.2% | 39.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 41.0% | ||
| Q2 24 | -83.9% | 47.9% |
| Q1 26 | — | $1.25 | ||
| Q4 25 | $0.32 | $1.28 | ||
| Q3 25 | $-0.16 | $0.97 | ||
| Q2 25 | $-0.06 | $0.60 | ||
| Q1 25 | $-0.21 | $0.93 | ||
| Q4 24 | $-0.14 | $1.84 | ||
| Q3 24 | $-0.15 | $1.17 | ||
| Q2 24 | $-0.33 | $1.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $83.2M |
| Total DebtLower is stronger | — | $32.0M |
| Stockholders' EquityBook value | $-302.0M | $2.3B |
| Total Assets | $465.9M | $20.3B |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $83.2M | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
| Q1 26 | — | $32.0M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.3B | ||
| Q4 25 | $-302.0M | $2.3B | ||
| Q3 25 | $-451.4M | $2.2B | ||
| Q2 25 | $-433.5M | $2.2B | ||
| Q1 25 | $-426.2M | $2.2B | ||
| Q4 24 | $-388.7M | $2.2B | ||
| Q3 24 | $-370.2M | $1.9B | ||
| Q2 24 | $-344.2M | $1.9B |
| Q1 26 | — | $20.3B | ||
| Q4 25 | $465.9M | $19.4B | ||
| Q3 25 | $364.0M | $19.4B | ||
| Q2 25 | $347.1M | $19.1B | ||
| Q1 25 | $324.0M | $18.8B | ||
| Q4 24 | $343.8M | $18.8B | ||
| Q3 24 | $314.1M | $18.7B | ||
| Q2 24 | $352.3M | $18.2B |
| Q1 26 | — | 0.01× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $-341.2M | ||
| Q3 25 | $-4.3M | $29.8M | ||
| Q2 25 | $-31.4M | $-121.2M | ||
| Q1 25 | $-22.6M | $148.0M | ||
| Q4 24 | $-35.0M | $-835.3M | ||
| Q3 24 | $-35.3M | $-492.6M | ||
| Q2 24 | $-7.2M | $51.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-362.2M | ||
| Q3 25 | — | $24.0M | ||
| Q2 25 | — | $-125.7M | ||
| Q1 25 | — | $141.2M | ||
| Q4 24 | — | $-853.7M | ||
| Q3 24 | $-35.5M | $-497.2M | ||
| Q2 24 | $-7.3M | $45.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | -195.5% | ||
| Q3 25 | — | 14.0% | ||
| Q2 25 | — | -70.1% | ||
| Q1 25 | — | 96.8% | ||
| Q4 24 | — | -440.6% | ||
| Q3 24 | -68.7% | -332.4% | ||
| Q2 24 | -9.9% | 28.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 11.3% | ||
| Q3 25 | 0.0% | 3.4% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.0% | 4.7% | ||
| Q4 24 | 0.0% | 9.5% | ||
| Q3 24 | 0.3% | 3.0% | ||
| Q2 24 | 0.1% | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | -3.19× | ||
| Q1 25 | — | 2.54× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -8.04× | ||
| Q2 24 | — | 0.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
MBIN
| Net Interest Income | $128.6M | 73% |
| Noninterest Income | $46.6M | 27% |
